[1]Milder TY,Stocker SL,Abdel Shaheed C,et al.Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes:a systematic review and meta-analysis[J].J Clin Med.2019,8(1):45.DOI:10.3390/jcm80100...
[1]Milder TY,Stocker SL,Abdel Shaheed C,et al.Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes:a systematic review and meta-analysis[J].J Clin Med.2019,8(1):45.DOI:10.3390/jcm8010045. [2]Guillausseau PJ.Influence of oral antidiabetic drugs compliance ...
13. Li X, Zhu X, Liu J, Li Q, et al. Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of Janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes...
[1]Milder TY,Stocker SL,Abdel Shaheed C,et al.Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes:a systematic review and meta-analysis[J].J Clin Med.2019,8(1):45.DOI:10.3390/jcm8010045. [2]Guillausseau PJ.Influence of oral antidiabetic drugs compliance ...
[1]Milder TY,Stocker SL,Abdel Shaheed C,et al.Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes:a systematic review and meta-analysis[J].J Clin Med.2019,8(1):45.DOI:10.3390/jcm8010045. [2]Guillausseau PJ.Influence of oral antidiabetic drugs compliance ...
发表期刊:《Diabetes Obes Metab》 影响因子:6.033 研究设计:这项多中心、随机、双盲、安慰剂对照研究纳入 432 例 HbA1c 在 7.0%～10.5% 的 T2DM 患者,按照 1:1:1 随机接受每日 1 次 Janagliflozin(25 mg 或 50 mg)或安慰剂治疗 24 周,随后安慰剂组患者再次随机化,按照 1:1 接受 25 mg 或 50 mg ...
[1]SGLT2 Inhibitor Diabetes Drugs May Cause Ketoacidosis[S]:FDA.Medscape.May 15, 2015. [2]EMA on Lowering Risk of Diabetic Ketoacidosis With SGLT2Inhibitors.Medscape.Feb 12, 2016. [3]Douros A, Lix LM, Fralick M,et al. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic...
[1]Milder TY,Stocker SL,Abdel Shaheed C,et al.Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes:a systematic review and meta-analysis[J].J Clin Med.2019,8(1):45.DOI:10.3390/jcm8010045. [2]Guillausseau PJ.Influence of oral antidiabetic drugs compliance ...
SGLT-2抑制剂可是在雷帕霉素、亚甲蓝和二甲双胍等药物中杀出重围，它在实验和临床应用中展现出巨大抗衰潜能，一举夺魁。然而，这位延寿抗衰的新科状元似乎因“私生活”过于低调，并不为大众所熟知，不过没关系，小编已打点好门路，将带您共同一睹其英姿。知其然，要知其所以然 ——SGLT-2和SGLT-2抑制剂 民以...
anti-diabetic drugsmetabolic disordersADRsdiabetes mellitusrisksSGLT2 inhibitorsBackground: Recently, Food and Drug Administration (FDA) has approved sodium/ glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes mellitus. However, regarding adverse drug reactions (ADRs) of SGLT2 ...